J&J, Basilea May Strike Deal On Phase III Antibiotic; FTC Pre-Approves
This article was originally published in The Pink Sheet Daily
Executive Summary
Ortho-McNeil and Basilea could partner on a broad-spectrum Phase III cephalosporin antibiotic, ceftobiprole (BAL5788)
You may also be interested in...
J&J, Basilea To Base Ceftobiprole Filing For Hospital-Acquired Pneumonia On Phase III Results
Despite positive results in patients with hospital-acquired pneumonia, the Phase III study failed to demonstrate non-inferiority in a high-risk subgroup.
J&J, Basilea To Base Ceftobiprole Filing For Hospital-Acquired Pneumonia On Phase III Results
Despite positive results in patients with hospital-acquired pneumonia, the Phase III study failed to demonstrate non-inferiority in a high-risk subgroup.
J&J Submits Ceftobiprole NDA
Novel cephalosporin would be used to treat complicated skin and skin structure infections, including diabetic foot infections.